Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04364737 · ClinicalTrials.gov registry record · Phase 2
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 941
- Enrollment target
NCT04364737 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 941 participants.
The verdict
NCT04364737, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 941 participants
- Enrollment target
Study Summary
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
Interventions
- BIOLOGICAL Convalescent Plasma
- OTHER Saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2020-04-17 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04364737
The ClinicalTrials.gov registry entry for NCT04364737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 941 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Convalescent Plasma is the first listed.
NCT04364737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04364737 about?
NCT04364737 is a clinical study titled "CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients". This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
What is the current status of trial NCT04364737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 941 participants. The study started on 2020-04-17. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT04364737?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL), Saline solution (OTHER).
Who is sponsoring clinical trial NCT04364737?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.